Sarah Sammons, MD, on breast cancer treatment | Dana-Farber Cancer Institute

Triple Negative MBC Research Update | 2024-2025 EMBRACE MBC Virtual Forum SeriesПодробнее

Navigating your First Year with MBC | 2023-2024 EMBRACE MBC Virtual Forum SeriesПодробнее

Welcome Session | 2024-2025 EMBRACE MBC Virtual Forum SeriesПодробнее

MBC: Staging, Progression, and Managing Scanxiety | 2023-2024 EMBRACE MBC Virtual Forum SeriesПодробнее

SABCS Snippets: Reflections on breast cancer advancements for 2023Подробнее

Integrative Medicine for Metastatic Breast Cancer | 2022-2023 EMBRACE MBC Virtual Forum SeriesПодробнее

What is Metastatic Breast Cancer? | Dana-Farber Cancer InstituteПодробнее

Research Update for ER-Positive MBC | 2023-2024 EMBRACE MBC Virtual Forum SeriesПодробнее

Olaparib + durvalumab as a chemotherapy-free maintenance strategy in platinum treated advanced TNBCПодробнее

Inflammatory Breast Cancer Q&A | 2023 Inflammatory Breast Cancer Program Patient ForumПодробнее

Immunotherapy for Inflammatory Breast Cancer | 2023 Inflammatory Breast Cancer Program Patient ForumПодробнее

Treatment goals and QOL in a survey of patients with ER+/HER2- mBCПодробнее

Research Update for Triple Negative MBC | 2022-2023 EMBRACE MBC Virtual Forum SeriesПодробнее

Clinical Trials 101 | 2022-2023 EMBRACE MBC Virtual Forum SeriesПодробнее

DORA: durvalumab and olaparib in platinum treated advanced TNBCПодробнее